Loading…
Loading the latest PSX data…
Loading the latest PSX data…
Liven Pharma Limited(Right) (LIVENR), GlaxoSmithKline Pakistan Limited (GLAXO), Abbott Laboratories (Pakistan) Limited (ABOT): performance, valuation, growth, risk and danioPSX score, side by side.
Add a stock
Growth of Rs 100 from 2025-12-01
Daily closes from PSX end-of-day files, adjusted for bonus shares, right issues and splits (not for cash dividends). KSE-100: official closes where available, otherwise rebuilt from its constituents.
| Measure | LIVENRPharmaceuticals | GLAXOPharmaceuticals | ABOTPharmaceuticals |
|---|---|---|---|
| danioPSX score | – | 89 | 81 |
| Price and size | |||
| Price | Rs 41.43 | Rs 336.00 | Rs 1,005.00 |
| Today | +2.47% | −1.06% | +0.11% |
| Market cap | Rs 829m | Rs 107.0bn | Rs 98.4bn |
| Traded per day | Rs 3m | Rs 49m | Rs 14m |
| Valuation and dividends | |||
| P/E | – | 9.7 | 10.6 |
| Dividend yield | – | 6.1% | 4.4% |
| EPS (last year) | – | Rs 31.48 | Rs 81.37 |
| Business | |||
| EPS growth | – | +53.4% | +52.2% |
| Sales growth | – | +7.7% | +10.6% |
| Net margin | – | 15.2% | 10.6% |
| Returns | |||
| 1 month | – | +8.9% | +7.5% |
| 3 months | – | −1.6% | +9.4% |
| 1 year | – | −13.9% | −8.1% |
| vs KSE-100, 1 year | – | -27.0 pts | -21.2 pts |
| Trend and risk | |||
| 52-week position | – | 28% | 40% |
| RSI 14 | – | 65 | 66 |
| RS rank | – | 42 | 65 |
| Volatility | – | 34% | 30% |
| Beta | – | 1.05 | 0.77 |
| danioPSX score | |||
| Value | – | 69 | 61 |
| Quality | – | 81 | 74 |
| Dividend | – | 64 | 34 |
| Momentum | – | 40 | 59 |
| Safety | – | 80 | 76 |
| Shariah-compliant | No | Yes | Yes |
Bold marks the best value in each row where higher (or, for P/E and volatility, lower) is clearly better.
A comparison of published numbers, not a recommendation. Share this page: the address holds the stocks. Find more stocks with the screener